Enveloped virus-like particle platforms: Vaccines of the future?

Expert Review of Vaccines

Volumn 14, Issue 7, 2015, Pages 913-915

  Pitoiset, Fabien ^a   Vazquez, Thomas ^b   Bellier, Bertrand ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

antigen platform; retrovirus; RTS S; vaccine development; virus like particles

Indexed keywords

EPITOPE; INACTIVATED VACCINE; LIVE VACCINE; SUBUNIT VACCINE; VIRUS VACCINE; VIRUS LIKE PARTICLE VACCINE;

ADAPTIVE IMMUNITY; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOTYPING; REVIEW; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS RECOMBINANT; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS; VACCINATION;

DRUG DISCOVERY; HUMANS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84931825857     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1046440     Document Type: Review

References (19)

1. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10(11):787-96
2. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011;365(20):1863-75
3. Gao X, Wang W, Li Y, et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res 2013;98(1):4-11
4. Jones RM, Chichester JA, Mett V, et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS ONE 2013;8(11):e79538
5. Matic S, Rinaldi R, Masenga V, et al. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 2011;11:106
6. Spohn G, Jennings GT, Martina BE, et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010;7:146
7. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012;31(1):58-83
8. Dalba C, Bellier B, Kasahara N, Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther J Am Soc Gene Ther 2007;15(3):457-66
9. Bellier B, Klatzmann D. Virus-like particle-based vaccines against hepatitis C virus infection. Expert Rev Vaccines 2013; 12(2):143-54
10. Garrone P, Fluckiger A-C, Mangeot PE, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011;3(94): 94ra71
11. Bachmann MF, Rohrer UH, Kündig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993; 262(5138):1448-51
12. Huret C, Desjardins D, Miyalou M, et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine 2013; 31(11):1540-7
13. Desjardins D, Huret C, Dalba C, et al. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med 2009;11(4): 313-25
14. Olsson S-E, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931-9
15. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the costa rica vaccine trial. Cancer Prev Res 2013; 6(11):1242-50
16. Kirchmeier M, Fluckiger AC, Soare C, et al. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol 2014;21(2):174-80
17. VBI Vaccines. Available from: www. vbivaccines.com
18. Bellier B, Dalba C, Clerc B, et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006; 24(14):2643-55
19. GeoVax. Available from: www.geovax.com